Here’s what you should know:
1. Oppenheimer revised its predictions from the initial $0.49 per share.
2. In addition, Oppenheimer gave Envision an “outperform” rating and a $40 price target on the stock.
3. Several other analysts published predictions, as well. Robert Baird reissued its “buy” rating, with a price target of $55. Bank of America decreased their target from $72 to $60 while also setting a “buy” rating on the stock.
4. In total, nine companies issued a “buy” rating, eight a “hold” rating and one a “sell” rating. The consensus is a “hold” rating, and a price target of $41.
More articles on transactions/valuations:
Effort to eliminate Mississippi’s CON law for ASCs tabled, but not dead
$10M gift sways Massachusetts hospital to dedicate outpatient center to donors
5 things to know about the trend toward microhospitals in 2018 — what does it mean for ASCs?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
